Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Atezolizumab + Bevacizumab
Treatment for Liver cancer due to hepatitis C
Typical Dosage: Atezolizumab 1200 mg IV every 3 weeks; Bevacizumab 15 mg/kg IV every 3 weeks
Effectiveness
78%
Safety Score
45%
Clinical Trials
50
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
Atezolizumab 1200 mg IV every 3 weeks; Bevacizumab 15 mg/kg IV every 3 weeks
Time to Effect
1-2 months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$215,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$240,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$190,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$879,121
Comparison vs Sorafenib
Cost Difference
+$170,000/year
More expensive
QALY Difference
+0.80 QALYs
Better outcomes
Dominance
No dominance
Atezolizumab + Bevacizumab Outcomes
for Liver cancer due to hepatitis C
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+27.3%
Common Side Effects
Hypertension
+25%
Fatigue
+25%
Diarrhea
+18%
Hemorrhage
+7%
Immune-related hepatitis
+4%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov